BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 12168892)

  • 1. Histological category and expression of hormone receptors in ductal carcinoma in situ of the breast.
    Lebrecht A; Buchmann J; Hefler L; Lampe D; Koelbl H
    Anticancer Res; 2002; 22(3):1909-11. PubMed ID: 12168892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
    Hanley K; Wang J; Bourne P; Yang Q; Gao AC; Lyman G; Tang P
    Hum Pathol; 2008 Mar; 39(3):386-92. PubMed ID: 18187183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
    Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
    Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
    Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M
    Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
    Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between hormone receptor status and tumour size, grade and comedo necrosis in ductal carcinoma in situ.
    Barnes NL; Boland GP; Davenport A; Knox WF; Bundred NJ
    Br J Surg; 2005 Apr; 92(4):429-34. PubMed ID: 15736216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
    Bircan S; Kapucuoglu N; Baspinar S; Inan G; Candir O
    Pathol Res Pract; 2006; 202(8):569-76. PubMed ID: 16828238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease?
    Bird PA; Hill AG; Houssami N
    Ann Surg Oncol; 2008 Jul; 15(7):1983-8. PubMed ID: 18408976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microsatellite alterations on human chromosome 11 in in situ and invasive breast cancer: a microdissection microsatellite analysis and correlation with p53, ER (estrogen receptor), and PR (progesterone receptor) protein immunoreactivity.
    Shen KL; Yang LS; Hsieh HF; Chen CJ; Yu JC; Tsai NM; Harn HJ
    J Surg Oncol; 2000 Jun; 74(2):100-7. PubMed ID: 10914818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of ER, PR and cyclin D1 in breast infiltrating ductal carcinoma and their clinicopathological significance].
    Wang ZB; Zhao P; Liu M; Li XH
    Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(8):514-7. PubMed ID: 15949328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.
    Gonzalez LO; Corte MD; Junquera S; Bongera M; Rodriguez JC; Vizoso FJ
    Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of estrogen and progesterone receptors in human ductal invasive breast carcinoma not otherwise specified: is there any difference between premenopausal and postmenopausal women?
    Petricević J; Petković M; Jonjić N
    Acta Clin Croat; 2011 Jun; 50(2):169-75. PubMed ID: 22263379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
    Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinicopathologic features and treatment of ductal carcinoma in situ of the breast].
    Zhou L; Wang Y; Song X; Du JW; Pei F; Huang LP; Wang WY; Liu ZB; Pan RQ
    Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3035-8. PubMed ID: 16324401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neu.
    Diallo R; Rody A; Jackisch C; Ting E; Schaefer KL; Kissler S; Karn T; Geddert H; Engels K; Kaufmann M; Gabbert HE; Shroyer KR; Poremba C
    Hum Pathol; 2006 Feb; 37(2):205-11. PubMed ID: 16426921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia.
    Gillett CE; Lee AH; Millis RR; Barnes DM
    J Pathol; 1998 Apr; 184(4):396-400. PubMed ID: 9664905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.
    Bijker N; Peterse JL; Duchateau L; Robanus-Maandag EC; Bosch CA; Duval C; Pilotti S; van de Vijver MJ
    Br J Cancer; 2001 Feb; 84(4):539-44. PubMed ID: 11207051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The receptor expression pattern in ductal carcinoma in situ predicts recurrence.
    Kepple J; Henry-Tillman RS; Klimberg VS; Layeeque R; Siegel E; Westbrook K; Korourian S
    Am J Surg; 2006 Jul; 192(1):68-71. PubMed ID: 16769278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.